Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus lenvatinib in previously treated HER2-expressing unresectable or metastatic biliary tract cancer
ChiCTR2300076406Phase 2Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Oct 2023
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and lenvatinib in biliary cancer, sponsored by Union Hospital. Primary endpoint: Objective response rate. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
disitamab vedotinlenvatinib
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2300076406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076406.